March 14, 2017 by Heather Lindsey Prostate organoids from genetically engineered mouse models. Credit: Mirjam Blattner and Dennis Huang

A newly discovered genetic mutation that is found in a subtype of prostate cancer is integral to the disease's development and growth, according to research from Weill Cornell Medicine scientists. Their findings could pave the way for new targeted treatment approaches.

A mutation of the gene Speckle Type BTB/POZ Protein, or SPOP, occurs in about 10 percent of men with prostate cancer. Roughly 20,000 men per year in the United States will be diagnosed with prostate cancers harboring SPOP mutations. But until now, SPOP's role in driving cancer was largely unknown. In a study published March 13 in Cancer Cell, researchers found in mice that the SPOP mutation leads to prostate cancer that grows in a distinctively different way from other common subtypes.

"This is important because now we have to think about SPOP cancers differently," said co-senior author Dr. Mark Rubin, director of the Caryl and Israel Englander Institute for Precision Medicine and the Homer T. Hirst III Professor of Oncology in Pathology at Weill Cornell Medicine. "This may have implications for how people respond to treatment and how amendable they are to certain drugs."

Prostate cancer containing the SPOP mutation was first discovered in 2011 by Weill Cornell Medicine researchers, who found that the malignancy has unique molecular features that characterize it as a distinct subtype.

"The key is we discovered these mutations several years ago, but because there are many mutations in cancer, knowing which ones are causing the disease and changing the biology of cells requires scientists to do some additional experiments," said co-senior author Dr. Christopher Barbieri, an assistant professor of urology at Weill Cornell Medicine.

In the new study, the research team, which included doctoral student and first author Mirjam Blattner, showed that the SPOP mutation drives prostate cancer formation in genetically engineered mice. This is a critical step in understanding the importance of mutations found in human cancers, Barbieri said. Additionally, they demonstrated that the SPOP mutation activates two major pathways in prostate cancer androgen receptor signaling and phosphoinositide 3-kinase (PI3K) signaling which are both important to cell survival and growth, and are processes that contribute to malignancy.

The androgen receptor is one of the main signaling pathways that underlies the growth of the prostate and prostate cancer, said Barbieri, who is a member of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine and a urologic surgeon at NewYork-Presbyterian/Weill Cornell Medical Center. Consequently, it is a main therapeutic target for men who have the disease. In recent years, researchers have shown that the androgen receptor works with the enzyme PI3K to promote prostate cancer cell survival.

Typically, these two pathways balance each other out, meaning the activation of one keeps the other in check and prevents cells from growing too out of control. "So, the fact that SPOP activates both pathways breaks the normal balance between the two, allowing cells to grow in an uncontrolled fashion," Barbieri said.

Now that scientists have a better understanding of the signaling pathways that are activated in this prostate cancer subtype, "we could potentially design therapies for it or use combinations of therapies that already exist to successfully target the cancer," Barbieri said.

The researchers are evaluating clinical trial data of patients being treated with androgen receptor antagonists and PI3K inhibitors to see whether they have SPOP mutations and how well they are responding to treatment. They're also investigating new agents to directly target SPOP cancers, pursuing a precision medical approach to treatment.

"This is a significant advancement for precision oncology," said Dr. Howard R. Soule, executive vice president and chief science officer of the Prostate Cancer Foundation, which helped fund the study through three research awards to Rubin and Barbieri. "Dr. Barbieri, Dr. Rubin, Blattner and team have identified the molecular mechanisms by which SPOP gene mutations, which define one of the most frequently occurring prostate cancer subtypes, drive prostate cancer. This provides a roadmap for developing precision treatment strategies for patients with this tumor type, which may shift towards improved outcomes."

Explore further: Gene mutation can allow proteins to gather, spark tumor growth

More information: http://www.cell.com/cancer-cell/fulltext/S1535-6108(17)30047-8

Journal reference: Cancer Cell

Provided by: Cornell University

Prostate cancer is generally treated as if it's a single disease. But researchers have discovered a new type of the cancer that appears to affect 15 percent of patients, a finding that paves the way for better diagnosis and ...

Mayo Clinic researchers have shed light on a new mechanism by which prostate cancer develops in men. Central to development of nearly all prostate cancer cases are malfunctions in the androgen receptorthe cellular component ...

Mutations in a protein called SPOP (speckle-type POZ protein) disarm it, allowing another protein called steroid receptor coactivator-3 (SRC-3) to encourage the proliferation and spread of prostate cancer cells, said researchers ...

The gene SPOP is mutated in up to 15 percent of all cases of prostate cancer, making it one of the most mutated genes in the disease. However, when the gene is functioning properly, it acts as a tumor suppressor. Despite ...

A collaborative expedition into the deep genetics of prostate cancer has uncovered a distinct subtype of the disease, one that appears to account for up to 15 percent of all cases, say researchers at Weill Cornell Medical ...

The steroid dexamethasone could potentially deter the growth of a prostate cancer subtype that was previously thought to be difficult to treat with medications, Weill Cornell Medicine researchers report. Their findings were ...

A new study reveals that African-Americans have measurable differences in the number and type of bacteria that live in the colon - and those differences are related to their higher-than-average colon cancer risk.

Many cancer patients that receive chemotherapy go into remission at first, but relapse after treatment is discontinued. There is increasing evidence that this is due to the presence of cancer stem cellscells that reproduce ...

The first of a new class of medication that delivers a combination of drugs by nanoparticle may keep melanoma from becoming resistant to treatment, according to Penn State College of Medicine researchers.

For decades, lactate has been studied largely in the context of exercise, painted as a nagging metabolic byproduct that accumulates in the tissues and blood during workouts, stiffening muscles and hindering performance.

A clinical trial of an antibody-drug conjugate that combines the active portion of a chemotherapy drug with an antibody targeting a molecule expressed on tumor cells appears promising for the treatment of metastatic triple-negative ...

A newly discovered genetic mutation that is found in a subtype of prostate cancer is integral to the disease's development and growth, according to research from Weill Cornell Medicine scientists. Their findings could pave ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Link:
Gene mutation found to drive prostate cancer subtype - Medical Xpress